Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses

Author:

Parisi Saverio Giuseppe,Mengoli Carlo,Basso Monica,Vicenti IlariaORCID,Gatti Francesca,Scaggiante Renzo,Fiaschi LiaORCID,Giammarino FedericaORCID,Iannetta MarcoORCID,Malagnino VincenzoORCID,Zago Daniela,Dragoni FilippoORCID,Zazzi MaurizioORCID

Abstract

We report the time course of neutralizing antibody (NtAb) response, as measured by authentic virus neutralization, in healthcare workers (HCWs) with a mild or asymptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection diagnosed at the onset of the pandemic, with no reinfection throughout and after a three-dose schedule of the BNT162b2 mRNA vaccine with an overall follow-up of almost two years since infection. Forty-eight HCWs (median age 47 years, all immunocompetent) were evaluated: 29 (60.4%) were asymptomatic. NtAb serum was titrated at eight subsequent time points: T1 and T2 were after natural infection, T3 on the day of the first vaccine dose, T4 on the day of the second dose, T5, T6, and T7 were between the second and third dose, and T8 followed the third dose by a median of 34 days. NtAb titers at all postvaccination time points (T4 to T8) were significantly higher than all those at prevaccination time points (T1 to T3). The highest NtAb increase was following the first vaccine dose while subsequent doses did not further boost NtAb titers. However, the third vaccine dose appeared to revive waning immunity. NtAb levels were positively correlated at most time points suggesting an important role for immunogenetics.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference35 articles.

1. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences

2. Tracking SARS-CoV-2 Variants www.who.int/en/activities/tracking-SARS-CoV-2-variants

3. SARS-CoV-2 Delta Variant Now Dominant in Much of European Region; Efforts Must Be Reinforced to Prevent Transmission, Warns WHO Regional Office for Europe and ECDC www.euro.who.int/en/media-centre/sections/press-releases/2021/sars-cov-2-delta-variant-now-dominantin-much-of-european-region-efforts-must-be-reinforced-toprevent-transmission,-warns-who-regional-office-foreuropeand-ecdc

4. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variantof-concern

5. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson;Patel;Hum. Vaccin. Immunother.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3